ArticlePsychopharmacology2025
MiR-223-3p inhibits hippocampal neurons injury and exerts anti- anxiety/depression-like behaviors by directly targeting NLRP3.
Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Low-Sample Input miRNA Profiling in Extracellular Vesicles-Enriched Plasma Fractions from Older Adults With/out Cognitive Impairment.International journal of molecular sciences · 2026Article
- MicroRNA-223 Enhances Microglia-Dependent Clearance of Amyloid Beta Plaques and Ameliorates Behavioral Deficits in a Mouse Model of Alzheimer's Disease.bioRxiv : the preprint server for biology · 2026Article
- Exerkine-Mediated Regulation of the NLRP3 Inflammasome in Neuroprotection: Mechanistic Insights and the Role of Exercise.Molecular neurobiology · 2026Review
- Exercise mimetics: molecular mechanisms, biological and therapeutic effects.Molecular biomedicine · 2026Review
- Interplay between the HPA axis and inflammation as mechanisms therapeutic targets ofFrontiers in pharmacology · 2026Review
- The Association Between miRNA-223-3p Levels and Pain Severity in Fibromyalgia Syndrome: A Molecular Approach.International journal of molecular sciences · 2025Article
- Plasma miRNA Profiles in Chronically Treated Bipolar Disorder Patients: A Case-Control Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- miRNA dysregulation in depression: unraveling the interplay between neuroplasticity, HPA axis dysfunction, and neuroinflammation.Metabolic brain disease · 2025Review
- The role of genetic and epigenetic factors in sports-related muscle, bone, and brain injuries.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Anxiety/depression disorders are among the most common neuropsychiatric conditions, and inflammation plays a significant role in their regulation. The involvement of miRNAs in the initiation, progression, and outcomes of anxiety disorders has been widely reported. Here, a decline in miR-223-3p expression was noticed in both IL-8-induced HT-22 cells and a rat model of anxiety/depression disorders treated with chronic unpredictable mild stress (CUMS). Our findings indicate that the overexpression of miR-223-3p significantly alleviates the effects of IL-8 on cell viability, inflammation, and oxidative stress in HT-22 cells, as verified by CCK-8 assay, ELISA assay, and flow cytometry. Through bioinformatics and luciferase reporter assays, NLRP3 was identified as a direct target of miR-223-3p. The inhibition of NLRP3 significantly reduced IL-8-induced damage to hippocampal neurons, while overexpression of NLRP3 reversed the protective effects of miR-223-3p. Moreover, increasing miR-223-3p levels significantly attenuated CUMS-induced anxiety/depression -like behaviors, such as decreased time in center in the open field test (OFT) and decreased time in open arm in the plus-maze test (EPM). The overexpression of miR-223-3p resulted in significant reductions in TNF-α, IL-1β, and SOD levels, an increase in MDA activity, as well as upregulation of cyclic adenosine monophosphate (cAMP), phosphorylated cAMP response element-binding protein (p-CREB), and brain-derived neurotrophic factor (BDNF) in the hippocampus. Overexpression of NLRP3 also reversed the effects of miR-223-3p in vivo. Thus, our research suggests that miR-223-3p can improve anxiety/depression-like behavior and inhibit hippocampal neuronal injury by targeting NLRP3, demonstrating its considerable anti-anxiety potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.